Special Topics Homepage 2026
-
ATS 2026 Orlando Program Aims to Maintain Momentum from Recent Breakthroughs in ILD and IPF
on
Read more: ATS 2026 Orlando Program Aims to Maintain Momentum from Recent Breakthroughs in ILD and IPFThe ATS 2026 International Conference will spotlight a wide range of recent investigative and clinical advances in the treatment of interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF), including the development of nerandomilast, the first FDA-approved therapy for IPF in over a decade. Susan K. Mathai, MD, spoke with ATS Conference News to preview…
-
ATS 2026 Orlando Spotlights Recent Advancements in Pediatric ILD Treatments
on
Read more: ATS 2026 Orlando Spotlights Recent Advancements in Pediatric ILD TreatmentsTreating pediatric patients with ILD or IPF can require unique treatment considerations and innovations compared with the treatment of adult populations. The relative rarity of pediatric patients with ILD reveals an urgent need for education among pediatric subspecialty providers and primary care physicians about how to diagnose and treat these diseases in collaboration with pediatric…
-
Explore the Latest Developments in Bronchiectasis During ATS 2026 Orlando
on
Read more: Explore the Latest Developments in Bronchiectasis During ATS 2026 OrlandoIn August 2025, clinicians and researchers who treat patients with bronchiectasis reached a significant milestone with the FDA approval of brensocatib, the first treatment developed for non-cystic fibrosis bronchiectasis in adults and pediatric patients aged 12 and older. In an interview with ATS Conference News, Dan Belz, MD, MPH, explained the significance of this milestone…
-
ATS 2026 Orlando Sessions Examine Recent Insights and Unique Challenges for Treating COPD
on
Read more: ATS 2026 Orlando Sessions Examine Recent Insights and Unique Challenges for Treating COPDRecent reports show that chronic obstructive pulmonary disease (COPD) was the fifth leading cause of death in the United States in 2023, with 141,733 deaths related to the disease during that year. Additionally, treatments for the disease incur annual medical costs of approximately $24 billion for adults aged 45 and older. Spyridon Fortis, MD, PhD,…
-
ILD and IPF Lineup at ATS 2026 Orlando
on
Read more: ILD and IPF Lineup at ATS 2026 OrlandoATS 2026 Orlando offers a robust scientific program featuring a variety of scientific symposia, abstract presentations, and Meet the Expert sessions to examine the latest investigative insights and clinical challenges for treating ILD and IPF.